20103 ⎘
Medicinal preparations characterised by special physical form; Pills, tablets, discs, rods; Excipients; Inactive ingredients; Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Orodispersible dosage unit containing an estetrol component
#902CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION
#903Pharmaceutical compositions
#904PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES
#905Extended release midodrine hydrochloride compositions and methods of use
#906PHARMACEUTICAL COMPOSITION
#907Drug delivery system
#908Combination formulation of three antiviral compounds
#909ANTIDIABETIC MEDICATIONS
#910IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE
#911GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
#912Oral delivery of GLP-1 peptide analogs
#913Pharmaceutical compositions
#914Pharmaceutical compositions
#915FORMULATIONS OF AN LSD1 INHIBITOR
#916FORMULATIONS OF A COMPOUND AND USES THEREOF
#9173D printing methods for compartmented pharmaceutical dosage forms
#918Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
#919Melatonin mini-tablets and method of manufacturing the same
#920Melatonin mini-tablets and method of manufacturing the same
#921Immediate release dosage form
#922Oral dosage form
#923Iniparib formulations and uses thereof
#924ORALLY ADMINISTRABLE COMPOSITIONS COMPRISING CALCIUM
#925Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#926Solid dispersions comprising tacrolimus
#927Solid Pharmaceutical Compositions for Treating HCV
#928Formulations of 5-fluorocytosine and uses thereof
#929Oral formulations of pyrrolidine derivatives
#930Alpha keto acid compositions for treating hypo-albuminemia
#931Delayed release deferiprone tablets and methods of using the same
#932INTRAORAL RETENTIVE DISINTEGRATING SOLID PREPARATION, METHOD FOR PRODUCING SAME AND POWDER COMPOSITION USED IN SAID PRODUCTION METHOD
#933PHARMACEUTICAL CAPSULE CONTAINING AT LEAST TWO TABLETS
#934Single-layer oral dose of neuro-attenuating ketamine
#935Solid pharmaceutical compositions for treating HCV
#936Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#937Pharmaceutical formulations comprising CCR3 antagonists
#938SUSTAINED RELEASE COMPOSITIONS OF 4-AMINOPYRIDINE
#939Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
#940FORMULATION HAVING CONTROLLED, DELAYED RELEASE OF ACTIVE INGREDIENT
#941Pyridine derivatives
#942Delayed release deferiprone tablets and methods of using the same
#943Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
#944BI-LAYER PHARMACEUTICAL TABLET FORMULATION
#945PHARMACEUTICAL COMPOSITIONS
#946Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
#947Pharmaceutical compositions containing a DGAT1 inhibitor
#948Treatment of hair loss disorders with deuterated JAK inhibitors
#949Abuse deterrent oral solid dosage form
#950Directly compressible composition comprising microcrystalline cellulose
#951PHARMACEUTICAL COMPOSITIONS
#952Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
#953Pharmaceutical composition comprising ibrutinib
#954COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
#955Methylphenidate extended release chewable tablet
#956Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
#957ABUSE-PROOFED DOSAGE FORM
#958Delayed release deferiprone tablets and methods of using the same
#959PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF
#960PHARMACEUTICAL COMPOSITIONS AND METHODS FOR INDOLEAMINE, 2, 3-DIOXYGENASE INHIBITION AND INDICATIONS THEREFOR
#961Treatment of metabolic disorders in canine animals
#962Pharmaceutical tablet and production method thereof
#963POSITION-SPECIFIC ASYMMETRIC DEUTERIUM ENRICHED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS
#964Palatable oral veterinary compositions
#965TABLET CONTAINING FERRIC CITRATE
#966Extended release compositions comprising pyridostigmine
#967Preparation comprising vonoprazan
#968Immediate release abuse-deterrent granulated dosage forms
#969Oral pharmaceutical compositions of nicotinamide
#970Compositions comprising dexamethasone
#971GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
#972TRIPULSE RELEASE STIMULANT FORMULATIONS
#973Pharmaceutical composition for oral administration comprising enzalutamide
#974PHARMACEUTICAL COMPOSITIONS COMPRISING AFATINIB
#975Pharmaceutical composition comprising quinoline derivative or salt thereof
#976Pharmaceutical formulation containing gelling agent
#977Atropisomerism for increased kinase inhibitor selectivity
#978PHARMACEUTICAL COMPOSITIONS
#979Dry-binders for tablets based on polyethylene glycol-polyvinyl alcohol graft polymers, the production and use thereof
#980Mucoadhesive oral preparation
#981Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease
#982Modified release formulations containing drug-ion exchange resin complexes
#983Extended Release Highly Loaded Drug Compositions
#984Intravesical drug delivery device with retention frame and drug tablets
#985Deterring Abuse of Pharmaceutical Products and Alcohol
#986TWO SPEED MONOLITHIC SYSTEM FOR CONTROLLED RELEASE OF DRUGS
#987SUSTAINED RELEASE COMPOSITIONS OF 4-AMINOPYRIDINE
#988Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
#989SYNERGISTIC USE OF CANNABIS FOR TREATING MULTIPLE MYELOMA
#990Abuse deterrent immediate release capsule dosage forms
#991FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE
#992Oral dosage form
#993Stable tablet compositions of Sacubitril: Valsartan
#994BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
#995DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
#996HSP90 INHIBITOR ORAL FORMULATIONS AND RELATED METHODS
#997Dispersible compositions
#998ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME
#999Low-Dose Stable Formulations of Linaclotide
#1000Granulated composite, rapid release tablet and method for producing same
#1001Method for producing disintegrating particulate composition comprising acid-type carboxymethylcellulose, disintegrating particulate composition comprising acid-type carboxymethylcellulose, and orally disintegrating tablet including disintegrating particulate composition comprising acid-type carboxymethylcellulose
#1002COMPOSITIONS AND METHODS FOR TREATMENT OF ABNORMAL CELL GROWTH
#1003ABUSE-PROOFED ORAL DOSAGE FORM
#1004Extended release, abuse deterrent pharmaceutical compositions
#1005Non-solvated crystal, preparation method and application thereof
#1006Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
#1007Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
#1008N3-CYCLICALLY SUBSTITUTED THIENOURACILS AND USE THEREOF
#1009Tebipenem pivoxil immediate and modified release oral dosage forms
#1010Ceritinib formulation
#1011IMPROVED DRUG FORMULATIONS
#1012TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
#1013CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS
#1014GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN
#1015Multicomponent gummy compositions with hard core
#1016COMPOUND
#1017Amorphous solid dispersions
#1018Acrylic Polymer Formulations
#1019Extended release compositions comprising pyridostigmine
#1020Modified release preparations containing oxcarbazepine and derivatives thereof
#1021RESIDENT ARTICLES FOR GRAM-LEVEL DOSING
#1022IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE
#1023Use of sublingual dexmedetomidine for the treatment of agitation
#1024DRUG DELIVERY ARTICLES FOR GRAM-LEVEL DOSING
#1025RAPIDLY DISINTEGRATING FORMULATIONS AND METHODS OF USE
#1026Retrieval systems and related methods
#1027Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
#1028PAC-1 combination therapy
#1029Pharmaceutical composition of apixaban
#1030Tableted chewing gum suitable for active pharmaceutical ingredients
#1031Pharmaceutical Composition of Acetaminophen/Ibuprofen
#1032Modified or Targeted Release Formulations of Linaclotide
#1033Tablet dosage form for buccal absorption of active ingredients
#1034Oral tablet for delivery of active ingredients to the throat
#1035Tablet of sporoderm-removed ganoderma lucidum spore and preparation method thereof
#1036Pharmaceutical composition and method of manufacturing the same
#1037Controlled release pharmaceutical compositions comprising a fumaric acid ester
#1038Three-dimensional (3D) printing a pharmaceutical tablet
#1039Micromotors and nanomotors for gastrointestinal diagnosis and treatment applications
#1040PHARMACEUTICAL COMPOSITIONS OF 5-HT6 ANTAGONIST
#1041ORALLY DISINTEGRATING TABLET
#1042Complex disintegrant system for oral solid preparation and oral solid preparation comprising said complex disintegrant system
#1043Pharmaceutical formulations
#1044DROXIDOPA COMPOSITIONS AND METHODS
#1045Oral drug dosage form comprising various release profiles
#1046Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate
#1047DOSAGE FORMS COMPRISING ABIRATERONE ACETATE
#1048FORMULATIONS OF AN LSD1 INHIBITOR
#1049DIRECTLY COMPRESSIBLE MATRIX FOR THE PRODUCTION OF TABLETS HAVING EXTENDED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT
#1050ANTI-ALCOHOL-INDUCED DOSE DUMPING TABLET BASED ON POLYVINYL ALCOHOL
#1051Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
#1052FORMULATIONS/COMPOSITIONS COMPRISING A BTK INHIBITOR
#1053Pulsatile drug delivery system for treating morning akinesia
#1054TIOPRONIN ORAL COMPOSITION
#1055Compositions and methods for reducing overdose
#1056Shaped mass composition comprising exenatide
#1057SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR
#1058Formulation of a micro drop pill and the preparation method thereof
#1059PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR
#1060SOLID DISPERSIONS COMPRISING A SGC STIMULATOR
#1061CHEWABLE TABLET CONTAINING VITAMIN C SODIUM AND PREPARATION METHOD THEREOF
#1062Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
#1063Pharmaceutical resinate compositions and methods of making and using thereof
#1064GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
#1065Monomethylfumarate Prodrug Compositions
#1066Tamper resistant pharmaceutical formulations
#1067Compounds for cancer chemotherapeutic sensitization
#1068Selective bromodomain inhibition of fungal Bdf1
#1069Immediate release tablet of dofetilide
#1070Polymorphic forms of kinase inhibitor compound, pharmaceutical composition containing same, preparation method therefor and use thereof
#1071Peptide YY pharmaceutical formulations, compositions, and methods
#1072ORAL APPLICATION OF THIOPEPTCIN
#1073Non-extractable oral solid dosage forms
#1074Gastric residence systems for sustained delivery of adamantane-class drugs
#1075PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING LACTASE AND PROCESS FOR PRODUCING SAME
#1076Pharmaceutical composition comprising neptinib or salt thereof and method for controlling impurity thereof
#1077Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
#1078CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE
#1079Pharmaceutical compositions for N-propargylamine derivative
#1080Solid Pharmaceutical Compositions for Treating HCV
#1081Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
#1082Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists
#1083NERIDRONIC ACID AND OTHER BISPHOSPHONATES FOR TREATING COMPLEX REGIONAL PAIN SYNDROME AND OTHER DISEASES
#1084Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
#1085Compounds for the treatment of infection
#1086DPP IV inhibitor formulations
#1087Extruded immediate release abuse deterrent pill
#1088PHARMACEUTICAL COMPOSITIONS CONFIGURED TO DETER DOSAGE FORM SPLITTING
#1089TABLET FORMULATION FOR CGRP ACTIVE COMPOUNDS
#1090Additive composition for orally disintegrating tablet
#1091Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
#1092CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
#1093COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT
#1094Controlled release and taste masking oral pharmaceutical composition
#1095Amorphous solid dispersions
#1096Oral drug dosage form comprising drug in the form of nanoparticles
#1097Compositions comprising dexamethasone
#1098Sustained Release Formulation Of Naltrexone
#1099Nicotine tablet
#1100Formulations Containing Amorphous Dapagliflozin
#1101A NOVEL TREATMENT REGIMEN INVOLVING SAPROPTERIN DIHYDROCHLORIDE
#1102Tamper resistant pharmaceutical formulations
#1103Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
#1104Pharmaceutical compositions
#1105Treatment of hair loss disorders with deuterated JAK inhibitors
#1106THERAPEUTIC COMPOUNDS
#1107MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES
#1108Pharmaceutical Formulations Comprising CCR3 Antagonists
#1109Additive composition for orally disintegrating tablet
#1110Process for mesalazine solid formulations
#1111Modified release formulations containing drug-ion exchange resin complexes
#1112DRUG FORMULATIONS
#1113Crystalline form of compound suppressing protein kinase activity, and application thereof
#1114CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITIONS
#1115COMPOSITIONS AND METHODS OF PROVIDING THYROID HORMONE OR ANALOGS THEREOF
#1116Immediate release abuse-deterrent granulated dosage forms
#1117NOVEL PHARMACEUTICAL FORMULATIONS
#1118Alcohol-Resistant Formulations
#1119PHARMACEUTICAL COMPOSITIONS COMPRISING FERRIC CITRATE AND METHODS FOR THE PRODUCTION THEREOF
#1120Orodispersible dosage unit containing an estetrol component
#1121Formulations of a compound modulating kinases
#1122ANTIBIOTIC COMPOSITIONS COMPRISING METFORMIN AND METHODS OF USING THE COMPOSITIONS
#1123Once Daily Formulations Of Tetracyclines
#1124Delayed release deferiprone tablets and methods of using the same
#1125Sustained-Release Oral Dosage Forms for Low Aqueous Solubility Compounds
#1126Granules of an active substance with double taste-masking technique, method for the production thereof, and orodispersible tablets containing same
#1127OXO-PYRIDINE-DERIVATIVES AS FACTOR XIA INHIBITORS FOR THE TREATMENT OF THROMBOSIS
#1128Pharmaceutical compositions
#1129Controlled release pharmaceutical compositions comprising a fumaric acid ester
#1130Solid oral formulation of fenretinide
#1131Delayed release deferiprone tablets and methods of using the same
#1132Pharmaceutical formulation containing gelling agent
#1133PHARMACEUTICAL FORMULATIONS OF A BRUTONS TYROSINE KINASE INHIBITOR
#1134Formulations of (R)-2-amino-3-phenylpropyl carbamate
#1135Orally disintegrating tablets
#1136Immediate release pharmaceutical composition of iron chelating agents
#1137COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
#1138ABUSE-RESISTANT CONTROLLED-RELEASE OPIOID DOSAGE FORM
#1139Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR-Inhibitors
#1140Pharmaceutical Formulation Containing Gelling Agent
#1141PHARMACEUTICAL COMPOSITION OF DAPAGLIFLOZIN
#1142Gut health compositions
#1143Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
#1144Oral pharmaceutical compositions of mesalazine
#1145Procaspase 3 activation by combination therapy
#1146Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
#1147COMPOSITIONS OF DEFERASIROX
#1148CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
#1149CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
#1150CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
#1151Controlled Release Dosage Form for Once Daily Administration of Dimethyl Fumarate
#1152NERIDRONIC ACID FOR TREATING COMPLEX REGIONAL PAIN SYNDROME
#1153Formulations And Pharmacokinetics Of Deuterated Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
#1154Orally Disintegrating Tablet Formulation For Enhanced Bioavailability
#1155Metformin hydrochloride osmotic pump tablet and preparation method therefor
#1156FORMULATION OF TICAGRELOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
#1157CONTROLLED RELEASE COMPOSITIONS FOR TREATMENT OF COGNITIVE, EMOTIONAL, AND MENTAL AILMENTS AND DISORDERS
#1158PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF
#1159Solid dosage forms of vigabatrin
#1160Pharmaceutical formulation containing gelling agent
#1161Treatment of diabetes mellitus
#1162Compound to treat Sjogren's syndrome
#1163Stabilized formulations of CNS compounds
#1164Melatonin mini-tablets and method of manufacturing the same
#1165Medical chewing gum comprising cannabinoid
#1166Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
#1167Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
#1168SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN
#1169OVERDOSE PROTECTION AND ABUSE DETERRENT IMMEDIATE RELEASE DRUG FORMULATION
#1170Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
#1171Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
#1172DAILY FORMULATION OF LACOSAMIDE
#1173PHARMACEUTICAL FORMULATION CONTAINING IRRITANT
#1174Controlled release and taste masking oral pharmaceutical composition
#1175Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
#1176CHOLESTYRAMINE PELLETS, ORAL CHOLESTYRAMINE FORMULATIONS AND USE THEREOF
#1177Solid dosage formulations of an orexin receptor antagonist
#1178Formulation having controlled, delayed release of active ingredient
#1179Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
#1180Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof
#1181Methylphenidate extended release chewable tablet
#1182CONTROLLED DOSING OF CLOPIDOGREL WITH GASTRIC ACID INHIBITION THERAPIES
#1183SURFACTANT-FREE HIV PROTEASE INHIBITOR COMPOSITION AND METHOD OF MANUFACTURING THEREOF
#1184Pharmaceutical composition comprising sacubitril and valsartan
#1185ABUSE-PROOFED DOSAGE FORM
#1186PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT
#1187CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITIONS
#1188CERITINIB FORMULATION
#1189CONTROLLED RELEASE HYDROCODONE FORMULATIONS
#1190Apixaban solid composition and preparation method thereof
#1191Pharmaceutical compositions and methods for fabrication of solid masses comprising TNF-inhibiting antibodies
#1192CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITIONS
#1193Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
#1194Formulations of 5-fluorocytosine and uses thereof
#1195Pharmaceutical compositions comprising phenylaminopyrimidine derivative
#1196NOVEL CLONIDINE FORMULATION
#1197Controlled release and taste masking oral pharmaceutical composition
#1198Pharmaceutical Formulation Containing Gelling Agent
#1199PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
#1200Quick dissolving diphenhydramine oral dosage form